USANA Health Sciences, Inc. $USNA Shares Sold by Rhumbline Advisers

Key Points

• Rhumbline Advisers reduced its holdings in USANA Health Sciences by 26.5%, ending the quarter with 36,305 shares valued at approximately $979,000.
• Several hedge funds, including PNC Financial Services and Versant Capital Management, significantly increased their positions in USANA Health Sciences during the same quarter, reflecting growing institutional interest.
• USANA Health Sciences reported stronger-than-expected earnings of $0.74 per share in its latest quarterly results, surpassing estimates by $0.20 and generating revenues of $235.85 million.

Rhumbline Advisers cut its stake in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 26.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,305 shares of the company's stock after selling 13,085 shares during the period. Rhumbline Advisers owned approximately 0.19% of USANA Health Sciences worth $979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the stock. US Bancorp DE grew its position in shares of USANA Health Sciences by 13.1% in the first quarter. US Bancorp DE now owns 4,611 shares of the company's stock valued at $124,000 after purchasing an additional 535 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of USANA Health Sciences by 7.1% in the first quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock valued at $248,000 after purchasing an additional 606 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of USANA Health Sciences by 339.6% in the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock valued at $27,000 after purchasing an additional 771 shares in the last quarter. Martingale Asset Management L P grew its position in shares of USANA Health Sciences by 5.4% in the first quarter. Martingale Asset Management L P now owns 17,542 shares of the company's stock valued at $473,000 after purchasing an additional 900 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in shares of USANA Health Sciences by 542.5% in the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock valued at $31,000 after purchasing an additional 971 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 1,058 shares of the stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $29.10, for a total value of $30,787.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Mulham Mulham sold 3,515 shares of the stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total value of $106,363.90. Following the completion of the transaction, the insider owned 9,260 shares of the company's stock, valued at $280,207.60. The trade was a 27.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.63% of the company's stock.

USANA Health Sciences Stock Performance

Shares of USNA stock traded down $0.61 during trading hours on Tuesday, reaching $29.08. The company had a trading volume of 34,377 shares, compared to its average volume of 171,345. The stock has a fifty day moving average of $30.77 and a 200-day moving average of $29.50. The company has a market capitalization of $531.29 million, a price-to-earnings ratio of 16.20, a PEG ratio of 0.95 and a beta of 0.64. USANA Health Sciences, Inc. has a 12-month low of $23.10 and a 12-month high of $41.83.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.20. The company had revenue of $235.85 million during the quarter, compared to analyst estimates of $225.20 million. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. On average, analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.